Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FOG-001 (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin; Tipiracil/trifluridine
  • Indications Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Parabilis Medicines

    • Most Recent Events

    • 23 Jan 2025 According to a Parabilis Medicines media release, Preliminary Phase 1/2 data are expected to be shared publicly in 2025.
    • 23 Jan 2025 According to a Parabilis Medicines media release, company to present a trial-in-progress poster on the Company first-in-human clinical trial evaluating FOG-001 at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium taking place in San Francisco from January 23-25, 2025.
    • 14 Jan 2025 Results reporting early clinical data in a Parabilis Medicines media release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top